Literature DB >> 12450935

Three-dimensional characterization of pathologic lesions in pulmonary langerhans cell histiocytosis.

Marianne Kambouchner1, Francoise Basset, Joelle Marchal, Jean Francois Uhl, Allan J Hance, Paul Soler.   

Abstract

The characteristic lesions of pulmonary Langerhans cell histiocytosis (LCH) associate destructive granulomas containing large numbers of Langerhans cells and cysts. The lesions are usually considered to develop around small airways, and cysts are thought to result from destruction of the bronchiolar wall by the granulomatous reaction. However, the extent to which the granulomatous reaction is truly bronchocentric remains unknown, and the mode of formation of the cysts has not been defined. By using serial sections, this study aimed to explore further the relationships between pulmonary LCH lesions and distal airways, and the development of cysts. The results demonstrated that the granulomatous process of pulmonary LCH affected exclusively small airways, in an acinar distribution. The lesions extended without interruption along the bronchiolar axis, forming a continuous sheath around distal airways. The granulomatous reaction seemed to progress along the bronchiolar axis over time, extending the abnormalities in both the proximal and distal directions. Cystic lesions resulted from the destruction of the bronchiolar wall and progressive dilatation of the lumen, subsequently circumscribed by fibrous tissue. Because pulmonary LCH lesions affect and progressively destroy distal airways, it may be proper to consider the disease a bronchiolitis rather than an interstitial lung disorder.

Entities:  

Mesh:

Year:  2002        PMID: 12450935     DOI: 10.1164/rccm.2201050

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  11 in total

Review 1.  Rare lung diseases III: pulmonary Langerhans' cell histiocytosis.

Authors:  Stephen C Juvet; David Hwang; Gregory P Downey
Journal:  Can Respir J       Date:  2010 May-Jun       Impact factor: 2.409

Review 2.  Diffuse Cystic Lung Disease. Part II.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 21.405

Review 3.  Cardiothoracic manifestations of primary histiocytoses.

Authors:  Daniel Vargas; J Caleb Richards; Daniel Ocazionez; Arlene Sirajuddin; Lorna Browne; Carlos S Restrepo
Journal:  Br J Radiol       Date:  2016-09-26       Impact factor: 3.039

4.  MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis.

Authors:  Huan Liu; Andrew R Osterburg; Jennifer Flury; Zulma Swank; Dennis W McGraw; Nishant Gupta; Kathryn A Wikenheiser-Brokamp; Ashish Kumar; Abdellatif Tazi; Yoshikazu Inoue; Masaki Hirose; Francis X McCormack; Michael T Borchers
Journal:  JCI Insight       Date:  2020-02-27

Review 5.  Diffuse cystic lung diseases.

Authors:  Jay H Ryu; Xinlun Tian; Misbah Baqir; Kaifeng Xu
Journal:  Front Med       Date:  2013-05-11       Impact factor: 4.592

Review 6.  Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis.

Authors:  Jean-François Cordier
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

7.  A practical approach to cystic lung disease on HRCT.

Authors:  Peter Beddy; Judith Babar; Anand Devaraj
Journal:  Insights Imaging       Date:  2010-11-12

Review 8.  Pulmonary langerhans cell histiocytosis.

Authors:  Harpreet S Suri; Eunhee S Yi; Gregorz S Nowakowski; Robert Vassallo
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

9.  Persistent pulmonary interstitial emphysema in a case of Langerhans cell histiocytosis.

Authors:  Pooja Abbey; Mahender K Narula; Rama Anand; Jagdish Chandra
Journal:  Indian J Radiol Imaging       Date:  2014-04

Review 10.  Pulmonary Langerhans cell histiocytosis in adults: A case report.

Authors:  Feng-Feng Wang; Ya-Shuang Liu; Wei-Bo Zhu; Yan-Dong Liu; Yao Chen
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.